

Date: 23rd April, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned matter, we wish to inform you that the Company has incorporated a wholly owned subsidiary named Alembic Pharmaceuticals GmbH in Germany.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid incorporation is enclosed as Annexure – I.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary
Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

Annexure-I

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as specified in Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/II/3762/2026 dated January 30, 2026:

| Sr. No. | Particulars | |
|---------|---|--|
| i) | Name of the target entity, details in brief such as size, turnover etc | Alembic Pharmaceuticals GmbH. Share Capital: EUR 25,000 (Euros Twenty Five Thousand Only) divided into 25,000 shares each EUR 1.00 Turnover: Nil (yet to commence business operations) |
| ii) | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; | Not Applicable, this intimation is regarding the incorporation of wholly owned subsidiary of the Company. |
| iii) | Industry to which the entity being acquired belongs | Pharmaceuticals |
| iv) | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | To explore new business opportunities in this geography to promote, sale and distribute pharmaceuticals product(s) of the Company. |
| v) | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| vi) | Indicative time period for completion of the acquisition | Not applicable |

ALEMBIC PHARMACEUTICALS LIMITED

| | | |
|-------|---|--|
| vii) | Consideration - whether cash consideration or share swap or any other form and details of the same; | Investment in Share capital of the Company. |
| viii) | Cost of acquisition and/or the price at which the shares are acquired; | Not Applicable. |
| ix) | Percentage of shareholding / control acquired and / or number of shares acquired | The Company holds 100% in Alembic Pharmaceuticals GmbH |
| x) | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | Not applicable, as this intimation is about a newly incorporated entity. |

ALEMBIC PHARMACEUTICALS LIMITED